Skip to main content
Terug
ULIHF logo

The United Laboratories International Holdings Limited

Datakwaliteit: 100%
ULIHF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 1,70
€ 0,00 (0,00%)
Marktkapitalisatie: 3,35B
Dagbereik
€ 1,70 € 1,75
52-Weeksbereik
€ 1,43 € 2,35
Volume
29
50D / 200D Gem.
€ 1,79 / € 1,85
Vorige Slotkoers
€ 1,70

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 1,3 0,4
P/B 0,2 2,9
ROE % 19,6 3,7
Net Margin % 19,3 3,9
Rev Growth 5Y % 11,9 10,0
D/E 0,2 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 0,00
€ 0,00 – € 0,00
 17 B 0
FY2028 € 1,52
€ 1,29 – € 1,72
 15 B 1
FY2027 € 1,37
€ 1,16 – € 1,54
 14 B 1

Belangrijkste Punten

Revenue grew 11,91% annually over 5 years — strong growth
ROE of 19,61% — decent returns on equity
Net margin of 19,33% shows strong profitability
Debt/Equity of 0,22 — conservative balance sheet
Generating 1,33B in free cash flow
P/E of 1,26 — trading at a low valuation

Groei

Revenue Growth (5Y)
11,91%
Revenue (1Y)0,14%
Earnings (1Y)-1,54%
FCF Growth (3Y)3,07%

Kwaliteit

Return on Equity
19,61%
ROIC13,32%
Net Margin19,33%
Op. Margin22,65%

Veiligheid

Debt / Equity
0,22
Current Ratio1,83
Interest Coverage89,14

Waardering

P/E Ratio
1,26
P/B Ratio0,23
EV/EBITDA0,06
Dividend Yield0,06%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0,14% Revenue Growth (3Y) 10,18%
Earnings Growth (1Y) -1,54% Earnings Growth (3Y) 29,70%
Revenue Growth (5Y) 11,91% Earnings Growth (5Y) 39,47%
Profitability
Revenue (TTM) 13,76B Net Income (TTM) 2,66B
ROE 19,61% ROA 10,30%
Gross Margin 44,21% Operating Margin 22,65%
Net Margin 19,33% Free Cash Flow (TTM) 1,33B
ROIC 13,32% FCF Growth (3Y) 3,07%
Safety
Debt / Equity 0,22 Current Ratio 1,83
Interest Coverage 89,14 Dividend Yield 0,06%
Valuation
P/E Ratio 1,26 P/B Ratio 0,23
P/S Ratio 0,24 PEG Ratio -3,10
EV/EBITDA 0,06 Dividend Yield 0,06%
Market Cap 3,35B Enterprise Value 180,04M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 13,76B 13,74B 11,33B 9,70B 8,77B
Net Income 2,66B 2,70B 1,58B 988,10M 702,99M
EPS (Diluted) 1,46 1,49 0,87 0,54 0,40
Gross Profit 6,08B 6,33B 4,97B 4,21B 3,81B
Operating Income 3,12B 3,29B 2,02B 1,41B 1,23B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 25,83B 21,02B 18,98B 16,33B 14,96B
Total Liabilities 11,40B 8,27B 8,37B 6,99B 6,35B
Shareholders' Equity 14,39B 12,73B 10,61B 9,34B 8,61B
Total Debt 3,16B 1,50B 2,46B 1,84B 2,21B
Cash & Equivalents 6,33B 4,26B 4,74B 3,33B 3,00B
Current Assets 16,07B 13,79B 12,51B 9,99B 8,22B
Current Liabilities 8,77B 6,63B 7,03B 6,54B 4,86B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#238 of 820
54
Custom Contrarian Investing (David Dreman)
#458 of 658
16
Value Defensive Investing (Benjamin Graham)
#114 of 708
53

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026